- Home
- SG vs MGTX Comparison
SG vs MGTX Comparison
Compare SG & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SG | MGTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 635.7M | 744.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SG | MGTX |
|---|---|---|
| Price | $6.89 | $8.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $15.54 | ★ $23.83 |
| AVG Volume (30 Days) | ★ 4.3M | 643.1K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $685,184,000.00 | $27,417,000.00 |
| Revenue This Year | $4.14 | N/A |
| Revenue Next Year | $11.24 | $619.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.43 | ★ 96.83 |
| 52 Week Low | $5.14 | $4.55 |
| 52 Week High | $35.95 | $9.73 |
Technical Indicators
Market Signals| Indicator | SG | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 44.34 |
| Support Level | $6.59 | $8.25 |
| Resistance Level | $7.48 | $9.50 |
| Average True Range (ATR) | 0.40 | 0.56 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 40.45 | 21.32 |
Price Performance
Historical ComparisonAbout SG Sweetgreen Inc.
Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.